Imaging and clinical correlates with regorafenib in metastatic colorectal cancer.
Colorectal Neoplasms
/ blood supply
Humans
Magnetic Resonance Imaging
Neoplasm Metastasis
Neovascularization, Pathologic
/ drug therapy
Phenylurea Compounds
/ administration & dosage
Positron-Emission Tomography
Protein Kinase Inhibitors
/ administration & dosage
Pyridines
/ administration & dosage
Randomized Controlled Trials as Topic
Tomography, X-Ray Computed
Computed tomography
Magnetic resonance imaging
Metastatic colorectal cancer
Positron emission tomography
Regorafenib
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
13
01
2020
revised:
27
03
2020
accepted:
29
03
2020
pubmed:
12
4
2020
medline:
9
6
2020
entrez:
12
4
2020
Statut:
ppublish
Résumé
In colorectal cancer (CRC), imaging is important in determining tumor stage, selecting treatment strategies, and in assessing response to therapy. However, some challenges remain with established imaging techniques, such as computed tomography, and with some commonly used response criteria, such as Response Evaluation Criteria in Solid Tumors, which measures change in size of several target lesions instead of change in tumor morphology or metabolic function. In addition, these assessments are not typically conducted until after 8 weeks of treatment, meaning that potential non-responders are often not identified in a timely manner. Regorafenib, an oral tyrosine kinase inhibitor indicated for the treatment of metastatic CRC, blocks the activity of several protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumor immunity. Timely differentiation of regorafenib responders from non-responders using appropriate imaging techniques that recognize not only changes in tumor size but also changes in tumor density or vasculature, may reduce unnecessary drug-related toxicity in patients who are unlikely to respond to treatment. This review discusses the latest developments in computed tomography, magnetic resonance imaging, and positron emission tomography tumor imaging modalities, and how these aid in identifying patients with metastatic CRC who are responders or non-responders to regorafenib treatment.
Identifiants
pubmed: 32278232
pii: S0305-7372(20)30058-X
doi: 10.1016/j.ctrv.2020.102020
pii:
doi:
Substances chimiques
Phenylurea Compounds
0
Protein Kinase Inhibitors
0
Pyridines
0
regorafenib
24T2A1DOYB
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102020Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest SC reports grants from Bayer. DC reports grants from 4SC, Amgen, AstraZeneca, Bayer, Celgene, Clovis Oncology, Eli Lilly, Janssen, MedImmune, Merck, Merrimack Pharmaceuticals, and Sanofi. KK reports a non-financial advisory role with Bayer. EO reports presentation fees from Chugai Pharmaceutical, Eli Lilly, Merck, Taiho Pharma, and Takeda, and other relationships with Bayer Yakuhin. SS reports advisory board membership with Amgen, Bayer, Bristol-Myers Squibb, Celgene, CheckmAb, Clovis, Daiichi-Sankyo, Incyte, Merck, Novartis, Roche-Genentech, and Seattle Genetics. CT reports advisory board fees from Bayer. AH, SY-K, LS, TS, and NST declare no conflicts of interest.